| abstract |
The present disclosure provides methods of genetically engineering T cells, such as CD4+ T cells, for use in cell therapy. In some aspects, provided methods include one or more steps of culturing the cells under stimulating conditions, introducing the recombinant polypeptide into the cells via transduction or transfection, and culturing the cells under conditions that promote proliferation and/or expansion. . In some aspects, the incubation and/or culture is performed in the presence of recombinant IL-2. In some aspects, the provided method is an efficient and reliable means of generating genetically engineered T cells with a high success rate. |